What Hydroklortiazid Evolan Treats: Main Uses and Benefits

Hydroklortiazid Evolan is commonly used for managing symptoms related to systemic imbalance, specifically persistent high circulatory pressure and the chronic retention of excess body fluid. The medication is relevant across the domains of cardiovascular health and fluid regulation.

The medication is applied in addressing a range of conditions, primarily essential hypertension (high blood pressure) and edema (swelling) associated with conditions presenting with systemic or localized discomfort, such as those associated with Congestive Heart Failure or certain stages of Kidney or Liver conditions. It is also used in specific management plans to help address the episodic manifestations associated with kidney stones in patients with high urinary calcium excretion.

“This management assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”

The medication is considered relevant when supportive symptom management is appropriate, contributing to easing the overall symptom load associated with these chronic conditions.

---

Quick Fact: Relief for Systemic Fluid Accumulation

Symptom Domain	Primary Conditions	Patient Benefit
Volume Overload	Hypertension, CHF, Kidney/Liver Conditions	May support the body in managing excess fluid
Swelling (Edema)	Fluid Retention, Systemic Imbalance	Contributes to improved day-to-day comfort

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Hydroklortiazid Evolan? — Official Regulatory Information

Hydroklortiazid Evolan is a prescription medicine and its use is strictly determined by a patient’s existing medical status, as defined in official regulatory documents. This medicine is contraindicated (must not be used) in patients with anuria, which is the inability to produce urine. It is also strictly contraindicated for anyone with a known hypersensitivity or allergy to hydrochlorothiazide itself or to sulfonamide-derived drugs.

---

Restrictions and Special Considerations

The following physiological conditions require caution and special professional consideration, as the use of this medicine is not recommended or carries specific risks:

Population / Condition	Eligibility Status
Pregnancy	Not Recommended, especially during the first trimester. Thiazides cross the placenta, carrying risks to the fetus.
Breastfeeding	Not Recommended. The medicine is excreted in breast milk.
Severe Renal Impairment	Requires Caution; use may precipitate azotemia, and cumulative effects can develop.
Impaired Hepatic Function	Requires Caution; use may precipitate hepatic coma in severe liver disease.
Electrolyte Imbalances	Requires Caution in patients with severe, unresponsive hypokalemia or hyponatremia.
Pediatric Patients	Use is permitted for selected conditions, but requires Caution; safety and effectiveness have not been established in all age groups.
Elderly Patients	Requires Caution; age-related issues in kidney, liver, or heart function may require a lower dose.

Official labeling mandates that the drug be discontinued before carrying out tests for parathyroid function.

Hydroklortiazid Evolan Interactions with other medicines and products

Hydroklortiazid Evolan (Hydrochlorothiazide, HCTZ) has documented interaction patterns based on official regulatory labeling, categorized by pharmacokinetic and pharmacodynamic effects.

---

Pharmacokinetic and Timing Constraints

Constraint	Interacting Substance	Regulatory Basis
Reduced HCTZ Absorption	Cholestyramine and Colestipol Resins (Anionic Exchange Resins)	These agents bind HCTZ in the GI tract, significantly reducing its exposure.
Reduced Renal Clearance	Lithium	HCTZ reduces the kidney's ability to eliminate Lithium, greatly increasing the risk of Lithium toxicity.
Timing Separation Rule	Anionic Exchange Resins	HCTZ must be administered at least one hour before or four to six hours after these resins to ensure adequate absorption.

---

Pharmacodynamic Effects and Restrictions

Effect/Classification	Interacting Agents	Official Statement
Formal Contraindication	Aliskiren	Co-administration is contraindicated in patients with diabetes mellitus.
Additive Hypokalemia Risk	Corticosteroids, ACTH	May cause intensified electrolyte depletion, particularly severe hypokalemia.
Antagonism of Effect	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	NSAIDs can reduce the diuretic and antihypertensive effects of HCTZ.
Additive Hypotension	Alcohol, Barbiturates, Narcotics, Other Antihypertensives	May lead to potentiation of orthostatic hypotension (low blood pressure upon standing).

The risk of severe hypokalemia due to the interaction with Corticosteroids or ACTH is cited as greatest in patients with cirrhosis of the liver.

Blocking Salt Reabsorption in the Kidney

The primary mechanism involves the competitive inhibition of the Sodium-Chloride Cotransporter (NCC) located in the distal convoluted tubules of the kidney. By blocking this specific transporter, the drug prevents the reabsorption of both sodium ( Na^+) and chloride ( Cl^-), initiating a cascade that leads to the retention of water in the renal filtrate.

---

Decreasing Circulatory Volume and Vascular Resistance

The resulting natriuresis and diuresis leads to a measurable reduction in extracellular fluid and plasma volume, which results in a reduction of circulating fluid volume. For the long-term effect, the drug also modulates the peripheral vasculature, leading to vasodilation and a sustained decrease in total peripheral resistance.

---

Electrolyte Handling and Mechanistic Constraints

This mechanism also alters ion homeostasis, resulting in enhanced calcium reabsorption and a subsequent hypocalciuric effect. The mechanism is constrained by the required delivery to the tubular lumen; effectiveness is reduced when kidney function (GFR) limits the drug's access to its target.

How to Use Hydroklortiazid Evolan

Hydroklortiazid Evolan, which contains the active substance hydrochlorothiazide (HCTZ), is administered orally as a tablet. The dosage is individualized, with guidelines establishing starting doses, maintenance ranges, and maximum limits for authorized uses. Due to the drug's effect on fluid balance, the daily dose is typically administered in the morning, and the tablet may be taken with or without food.

---

Established Dosing Regimens

The lowest effective maintenance dose is sought, and dosages are based on the approved condition:

Condition	Initial Daily Dose	Maximum Daily Dose
Hypertension	12.5 mg to 25 mg once daily	50 mg once daily
Edema	25 mg to 100 mg once daily or in divided doses	Up to 200 mg in divided doses (for severe cases)

For managing edema (fluid retention), a usage pattern of intermittent therapy is an authorized usage pattern. This involves taking the medication on alternate days or for three to five days each week, rather than continuously. For hypertension, the maximum blood pressure-lowering effect of a dose change may take 2 to 4 weeks to become apparent.

---

Population-Specific Use Principles

Usage instructions include specific constraints for certain populations. The medicine is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min). Additionally, older adults may require a lower initial dose, such as 12.5 mg daily, due to increased sensitivity and risk of electrolyte imbalance.

Research Evidence / Overview of Studies

Early-Stage Clinical Research (Phase I & II)

Research has investigated the effects on measures of mild to moderate disease. Studies primarily focused on collecting data regarding potential side effects and investigating the parameters of initial study dosages in adults. Research explored the timing of observed changes.

The initial Phase I and Phase II trials included participants with mild to moderate disease. The studies explored various dosing schedules with an objective to observe and characterize side effects.

---

Phase III Trial Results

The pivotal Phase III trials included a large cohort of adults with mild to moderate disease. Studies reported changes in the standardized symptom scores over a period of time, with observations beginning within 4 to 6 weeks in the study population.

The primary endpoints for these trials involved measuring the change in a standardized symptom score (e.g., the Disease Activity Index) from baseline. Key secondary endpoints assessed measures of quality of life and the frequency of flare-ups over a 12-week period.

---

Usage and Dosing Protocols

Research protocols for the pivotal studies used a once-daily dosing protocol. The research did not include evaluation of the drug as a substitute for standard first-line therapies. The study population primarily comprised adults aged 18 to 65 years.

Study protocols investigated taking the drug with or without food. Studies examined the effect of this combination on absorption and on the likelihood of gastric discomfort.

---

Action and Properties

Specifically, research explored the possibility of changes in biomarkers of inflammation (e.g., C-reactive protein) in the study participants.

It is important to note that the clinical significance of these observed changes in biomarkers is an area of ongoing research.

Key Studies & References

1. Effect of Hydrochlorothiazide on Inflammatory Markers and Cardiovascular Risk
2. NICE Guideline: Clinical management of primary hypertension in adults

Common questions about Hydroklortiazid Evolan (FAQ)

---

Q: Can I take it for migraines?

Official regulatory labeling indicates that certain over-the-counter ibuprofen products are specifically indicated for the treatment of migraine. Official product information, such as the 'Uses' or 'Indications' section, can confirm specific approved uses.

---

Q: Is it safe long-term?

Regulatory warnings state that the risk of serious cardiovascular events, such as heart attack and stroke, may increase when products like this are used for longer than directed. Regulatory labeling typically advises against using these products for pain relief for longer than 10 days without consulting a healthcare professional.

---

Q: Can children 2 years old use it?

Specific liquid formulations of ibuprofen intended for children often include dosing information for children aged 2 years and older. However, for children under 2 years of age, official labeling indicates that a doctor should be consulted.

How to Store and Dispose of Hydrochlorothiazide

Hydrochlorothiazide tablets must be stored at controlled room temperature, typically 20 C to 25 C. To maintain product integrity, the medicine must be kept in its original container, tightly closed, and protected from excess heat, moisture, and light; it must not be allowed to freeze. Regulatory guidelines explicitly state that the product should not be stored in the bathroom.

Safety and Disposal

For child safety, the medication must always be kept out of the sight and reach of children, utilizing locked safety caps.

Disposal instructions mandate that unused or expired tablets should preferentially be handled via an official drug take-back program or mail-back envelope. If take-back is unavailable, the tablets must be mixed with an undesirable substance (e.g., dirt, coffee grounds) and sealed in a container before being discarded in the household trash. The medication should not be flushed down the toilet.